Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Détails
Télécharger: BIB_8411D80B9994.P001.pdf (5415.60 [Ko])
Etat: Public
Version: Final published version
Etat: Public
Version: Final published version
ID Serval
serval:BIB_8411D80B9994
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Périodique
Cell Reports
ISSN
2211-1247 (Electronic)
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
9
Numéro
1
Pages
75-89
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Prosenescence therapy has recently emerged as a novel therapeutic approach for treating cancer. However, this concept is challenged by conflicting evidence showing that the senescence-associated secretory phenotype (SASP) of senescent tumor cells can have pro- as well as antitumorigenic effects. Herein, we report that, in Pten-null senescent tumors, activation of the Jak2/Stat3 pathway establishes an immunosuppressive tumor microenvironment that contributes to tumor growth and chemoresistance. Activation of the Jak2/Stat3 pathway in Pten-null tumors is sustained by the downregulation of the protein tyrosine phosphatase PTPN11/SHP2, providing evidence for the existence of a novel PTEN/SHP2 axis. Importantly, treatment with docetaxel in combination with a JAK2 inhibitor reprograms the SASP and improves the efficacy of docetaxel-induced senescence by triggering a strong antitumor immune response in Pten-null tumors. Altogether, these data demonstrate that immune surveillance of senescent tumor cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments.
Mots-clé
Animals, Antineoplastic Agents/pharmacology, Cell Aging/immunology, Cytokines/immunology, Female, Gene Expression Profiling, Humans, Male, Mice, Mice, Transgenic, PTEN Phosphohydrolase/deficiency, PTEN Phosphohydrolase/immunology, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms/genetics, Signal Transduction, Taxoids/pharmacology, Tumor Microenvironment
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/10/2016 15:03
Dernière modification de la notice
20/08/2019 14:43